Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more
Vanda Pharmaceuticals Inc (VNDA) - Total Liabilities
Latest total liabilities as of December 2025: $161.76 Million USD
Based on the latest financial reports, Vanda Pharmaceuticals Inc (VNDA) has total liabilities worth $161.76 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vanda Pharmaceuticals Inc - Total Liabilities Trend (2004–2025)
This chart illustrates how Vanda Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vanda Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Vanda Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hwaxin Environmental Co. Ltd. A
SHE:301265
|
China | CN¥257.00 Million |
|
Regenxbio Inc
NASDAQ:RGNX
|
USA | $363.75 Million |
|
Potbelly Co
NASDAQ:PBPB
|
USA | $204.14 Million |
|
PT Berkah Beton Sadaya Tbk
OTCQX:BHBSY
|
USA | $88.66 Billion |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
Taiwan | NT$5.07 Billion |
|
Hunan Baili Engineering Sci
SHG:603959
|
China | CN¥2.44 Billion |
|
Der International Home Furnishing Co Ltd
SHE:002631
|
China | CN¥1.09 Billion |
|
Timbercreek Financial Corp
PINK:TBCRF
|
USA | $1.07 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Vanda Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vanda Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vanda Pharmaceuticals Inc (2004–2025)
The table below shows the annual total liabilities of Vanda Pharmaceuticals Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $161.76 Million | +37.48% |
| 2024-12-31 | $117.66 Million | +13.65% |
| 2023-12-31 | $103.53 Million | -3.29% |
| 2022-12-31 | $107.05 Million | +20.46% |
| 2021-12-31 | $88.86 Million | +10.82% |
| 2020-12-31 | $80.19 Million | +10.15% |
| 2019-12-31 | $72.80 Million | +28.38% |
| 2018-12-31 | $56.71 Million | -23.41% |
| 2017-12-31 | $74.04 Million | -6.33% |
| 2016-12-31 | $79.04 Million | -1.22% |
| 2015-12-31 | $80.02 Million | +635.03% |
| 2014-12-31 | $10.89 Million | -89.03% |
| 2013-12-31 | $99.22 Million | -20.96% |
| 2012-12-31 | $125.54 Million | -15.82% |
| 2011-12-31 | $149.14 Million | -14.96% |
| 2010-12-31 | $175.37 Million | -13.48% |
| 2009-12-31 | $202.68 Million | +5078.99% |
| 2008-12-31 | $3.91 Million | -70.20% |
| 2007-12-31 | $13.13 Million | +38.18% |
| 2006-12-31 | $9.50 Million | +86.78% |
| 2005-12-31 | $5.09 Million | +181.31% |
| 2004-12-31 | $1.81 Million | -- |